Four pegylated drugs approved by FDA in the last five years

  • Plegridy (Biogen 2014) — PEGylated Interferon Beta-1a for the treatment of patients with relapsing forms of multiple sclerosis.
  • Naloxegol (Movantik) (AstraZeneca 2014) — PEGylated naloxol for the treatment of opioid-induced constipation in adults patients with chronic non-cancer pain.
  • Pegnesatide (Omontys) (Takeda Pharmaceuticals, 2012) — To treat anemia associated with chronic kidney disease in adult patients on dialysis.
  • Pegloticase (Krystexxa) (Savient 2010) — PEGylated uricase for the treatment of gout.